**Sarepta Therapeutics Faces Increased Scrutiny After Patient Deaths**
Sarepta Therapeutics Inc. is under heightened scrutiny following the death of another patient from acute liver failure linked to one of its gene therapies. This incident adds to the recent tragic deaths of two teenage boys who also suffered from acute liver failure while undergoing treatment with the company’s gene therapy, Elevidys, which is designed for Duchenne muscular dystrophy.
The latest patient death occurred last month during an early-stage trial aimed at treating limb-girdle muscular dystrophy, a condition that weakens muscles around the hips and shoulders. A spokesperson for Sarepta confirmed that the company promptly informed regulators and investigators about the incident. “While we do everything possible to ensure patient safety, there is inherent risk in clinical trials, and we are grateful to the courageous patients and families who participate,” the spokesperson stated.
Sarepta has been facing significant pressure since the fatalities of the two teenage boys, both of whom were unable to walk due to the muscle-wasting disease. In response to these concerns, the company announced on Wednesday that it would issue warnings to doctors and patients regarding the risk of liver failure associated with Elevidys, following a request from the U.S. Food and Drug Administration (FDA). During a call with analysts, Sarepta executives indicated that the updated warning label seemed to address the FDA’s concerns about using the gene therapy in children who can walk.
In a significant restructuring move, Sarepta also revealed plans to reduce its workforce by more than a third and pause several projects in its drug pipeline, aiming for an estimated $400 million in annual cost savings. The company is continuing discussions with the FDA to address safety concerns for the segment of the Duchenne muscular dystrophy market involving patients who can no longer walk.
As Sarepta navigates these challenges, the implications for its future and the safety of its therapies remain a critical focus for stakeholders and the medical community.
**FAQ**
**What is the current status of Sarepta Therapeutics’ gene therapies?**
Sarepta Therapeutics is currently facing scrutiny due to patient deaths linked to its gene therapies. The company is working with the FDA to address safety concerns and has implemented new warning measures for its treatments.
